Belzutifan
Placeholder slot
(bel-ZOO-tih-fan)This page contains brief information about belzutifan and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
US Brand Name(s)
Welireg
FDA Approved
Yes
FDA label information for this drug is available at DailyMed.
Use in Cancer
Belzutifan is approved to treat:
- Cancers in adults linked to von Hippel-Lindau disease that require treatment but not immediate surgery, including:
- Central nervous system hemangioblastoma.
- Pancreatic neuroendocrine tumors.
- Renal cell carcinoma.
- Pheochromocytoma or paraganglioma that has spread or cannot be removed by surgery. It is used in adults and children aged 12 years and older.
- Renal Cell Carcinoma that is advanced. It is used in adults who have been treated with anti-VEGF therapy and either anti-PD-1 or anti-PD-L1 therapy.
Belzutifan is also being studied in the treatment of other types of cancer.
More About Belzutifan
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Belzutifan - A lay language summary of important information about this drug.
Research Results and Related Resources
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Belzutifan - Check for trials from NCI's list of cancer clinical trials now accepting patients.